Immunocompromised patients lack critical components of the adaptive and/or innate immune system required to counteract infection. These deficits can also reduce the effectiveness of vaccinations to less than 50%.6
Patients with bacterial or viral co-infections are more likely to progress to lower respiratory illness, suffer life-threatening disease, and experience prolonged hospitalizations.8,12
Learn about the advantages and limitations of management strategies for RVI in immunocompromised patients.
Images and descriptions are for illustrative purposes only
HSCT, hematopoietic stem cell transplant; RSV, respiratory syncytial virus; RVI, respiratory viral infection.
1. Centers for Disease Control and Prevention. Disease burden of influenza. Accessed February 2, 2021. https://www.cdc.gov/flu/about/burden/index.html. 2. Henrickson KJ. Clin Microbiol Rev. 2003;16(2):242-264. 3. Edwards KM, et al. N Engl J Med. 2013;368(7):633‐643. 4. Centers for Disease Control and Prevention. Respiratory syncytial virus infection: trends and surveillance. Accessed February 2, 2021. https://www.cdc.gov/rsv/research/us-surveillance.html. 5. Killerby ME, et al. J Clin Virol. 2018;101:52-56. 6. Centers for Disease Control and Prevention. Immunogenicity, Efficacy, and Effectiveness of Influenza Vaccines. Accessed February 2, 2021. https://www.cdc.gov/flu/professionals/acip/immunogenicity.htm. 7. Martínez-Roig A, et al. Arch Bronconeumol. 2015;51(1):5-9. 8. Wiegers HMG, et al. BMC Infect Dis. 2019;19(1):938. 9. Choi SH, et al. Am J Respir Crit Care Med. 2012;186(4):325‐332. 10. Walker E, et al. Influenza Other Respir Viruses. 2014;8(3):282‐292. 11. Griffiths C, et al. Clin Microbiol Rev. 2017;30(1):277-319. 12. Mazur NI et al. Clin Infect Dis. 2017;64(4):443-450 13. Lewinsohn DM, et al. Antimicrob Agents Chemother. 1996;40(11):2555-2557. 14. Khalifah AP, et al. Am J Respir Crit Care Med. 2004;170(2):181‐187. 15. Whimbey E, et al. Clin Infect Dis. 1995;21(2):376-379.